Zevra Therapeutics, Inc. — Revenue by Fiscal Year
11 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/d9ccee7e-f346-4c22-9902-b9a5f751dab3/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $106.5M | 2025-01-01 – 2025-12-31 | evidence 0001434647-26-000011 |
| FY 2024 | $23.6M | 2024-01-01 – 2024-12-31 | evidence 0001437749-25-007320 |
| FY 2023 | $27.5M | 2023-01-01 – 2023-12-31 | evidence 0001437749-24-010430 |
| FY 2022 | $10.2M | 2022-01-01 – 2022-12-31 | evidence 0001437749-24-010430 |
| FY 2021 | $28.6M | 2021-01-01 – 2021-12-31 | evidence 0001437749-22-007725 |
| FY 2020 | $13.3M | 2020-01-01 – 2020-12-31 | evidence 0001437749-21-005785 |
| FY 2019 | $12.8M | 2019-01-01 – 2019-12-31 | evidence 0001437749-20-003965 |
| FY 2018 | $0 | 2018-01-01 – 2018-12-31 | evidence 0001437749-20-003965 |
| FY 2015 | $0 | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-014881 |
| FY 2014 | $0 | 2014-01-01 – 2014-12-31 | evidence 0001564590-16-014881 |
| FY 2013 | $0 | 2013-01-01 – 2013-12-31 | evidence 0001564590-16-014881 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Zevra Therapeutics, Inc. — all facts · Net Income · Operating Income